388 related articles for article (PubMed ID: 26870930)
1. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.
Wree A; Mehal WZ; Feldstein AE
Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
Fuchs CD; Traussnigg SA; Trauner M
Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
[TBL] [Abstract][Full Text] [Related]
3. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment.
Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K
Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219
[TBL] [Abstract][Full Text] [Related]
4. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution.
Musso G; Gambino R; Cassader M; Paschetta E; Sircana A
Trends Pharmacol Sci; 2018 Apr; 39(4):387-401. PubMed ID: 29499974
[TBL] [Abstract][Full Text] [Related]
5. Macrophages in Nonalcoholic Fatty Liver Disease: A Role Model of Pathogenic Immunometabolism.
Krenkel O; Tacke F
Semin Liver Dis; 2017 Aug; 37(3):189-197. PubMed ID: 28847030
[No Abstract] [Full Text] [Related]
6. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
8. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
[TBL] [Abstract][Full Text] [Related]
9. An update on the recent advances in antifibrotic therapy.
Tacke F; Weiskirchen R
Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1143-1152. PubMed ID: 30261763
[TBL] [Abstract][Full Text] [Related]
10. Management strategies for liver fibrosis.
Altamirano-Barrera A; Barranco-Fragoso B; Méndez-Sánchez N
Ann Hepatol; 2017; 16(1):48-56. PubMed ID: 28051792
[TBL] [Abstract][Full Text] [Related]
11. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.
Musso G; Cassader M; Gambino R
Nat Rev Drug Discov; 2016 Apr; 15(4):249-74. PubMed ID: 26794269
[TBL] [Abstract][Full Text] [Related]
13. Review. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver disease.
Sun X; Zhang Y; Xie M
Acta Pharm; 2017 Mar; 67(1):1-13. PubMed ID: 28231052
[TBL] [Abstract][Full Text] [Related]
14. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies.
Wattacheril J; Issa D; Sanyal A
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():649-662. PubMed ID: 29058997
[TBL] [Abstract][Full Text] [Related]
16. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
[TBL] [Abstract][Full Text] [Related]
17. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
Sundaram V; Morgan TR
Clin Liver Dis; 2019 Feb; 23(1):157-165. PubMed ID: 30454829
[TBL] [Abstract][Full Text] [Related]
18. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
[TBL] [Abstract][Full Text] [Related]
19. Future trends in the treatment of non-alcoholic steatohepatitis.
Fiorucci S; Biagioli M; Distrutti E
Pharmacol Res; 2018 Aug; 134():289-298. PubMed ID: 30021122
[TBL] [Abstract][Full Text] [Related]
20. Pharmacotherapy for Nonalcoholic Fatty Liver Disease.
Gawrieh S; Chalasani N
Semin Liver Dis; 2015 Aug; 35(3):338-48. PubMed ID: 26378648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]